Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Kulasekararaj AG, et al. Blood. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805. Epub 2018 Dec 3. Blood. 2019. PMID: 30510079 Free PMC article. Clinical Trial.
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E, Martens C, Sparling A, Webster KA, Cella D, Tomazos I, Ogawa M, Piatek CI, Wells R, Sicre de Fontbrune F, Röth A, Mitchell L, Hill A, Kaiser K. Peipert JD, et al. PLoS One. 2020 Sep 4;15(9):e0237497. doi: 10.1371/journal.pone.0237497. eCollection 2020. PLoS One. 2020. PMID: 32886668 Free PMC article. Clinical Trial.
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG, Hill A, Langemeijer S, Wells R, González Fernández FA, Gaya A, Ojeda Gutierrez E, Piatek CI, Mitchell L, Usuki K, Bosi A, Brodsky RA, Ogawa M, Yu J, Ortiz S, Röth A, Lee JW, Peffault de Latour R. Kulasekararaj AG, et al. Eur J Haematol. 2021 Mar;106(3):389-397. doi: 10.1111/ejh.13564. Epub 2021 Jan 3. Eur J Haematol. 2021. PMID: 33301613 Free PMC article. Clinical Trial.
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, Yu J, Mujeebuddin A, Nishimura JI, Lee JW, Peffault de Latour R; 301/302 Study Group. Kulasekararaj AG, et al. Eur J Haematol. 2022 Sep;109(3):205-214. doi: 10.1111/ejh.13783. Epub 2022 Jun 16. Eur J Haematol. 2022. PMID: 35502600 Free PMC article. Clinical Trial.
Two new mutations in the GLRX5 gene cause sideroblastic anemia.
Melo Arias AF, Escribano Serrat S, Martínez Nieto J, Medina Salazar F, Ropero Gradilla P, Benavente Cuesta C, González Fernández FA. Melo Arias AF, et al. Among authors: gonzalez fernandez fa. Blood Cells Mol Dis. 2023 Sep;102:102763. doi: 10.1016/j.bcmd.2023.102763. Epub 2023 Jun 2. Blood Cells Mol Dis. 2023. PMID: 37301020 No abstract available.
Clinical and genetic features of congenital dyserythropoietic anemia (CDA).
Moreno-Carralero MI, Horta-Herrera S, Morado-Arias M, Ricard-Andrés MP, Lemes-Castellano A, Abio-Calvete M, Cedena-Romero MT, González-Fernández FA, Llorente-González L, Periago-Peralta AM, de-la-Iglesia-Íñigo S, Méndez M, Morán-Jiménez MJ. Moreno-Carralero MI, et al. Eur J Haematol. 2018 Sep;101(3):368-378. doi: 10.1111/ejh.13112. Epub 2018 Jul 27. Eur J Haematol. 2018. PMID: 29901818
Red blood cell disorders in recently arrived African immigrants to Gran Canaria, Spain.
de-la-Iglesia-Iñigo S, Carranza-Rodriguez C, Ropero-Gradilla P, González-Fernandez FA, Molero-Labarta T, Hemmersbach-Miller M, Pérez-Arellano JL. de-la-Iglesia-Iñigo S, et al. Trans R Soc Trop Med Hyg. 2013 Feb;107(2):91-7. doi: 10.1093/trstmh/trs017. Epub 2012 Nov 6. Trans R Soc Trop Med Hyg. 2013. PMID: 23222950
A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M, Tortajada A, Gastoldi S, Galbusera M, López-Perrote A, Lopez Lde J, González-Fernández FA, Villegas-Martínez A, Dominguez M, Llorca O, Noris M, Morgan BP, Rodríguez de Córdoba S. Subías M, et al. J Immunol. 2014 Dec 1;193(11):5567-75. doi: 10.4049/jimmunol.1402013. Epub 2014 Oct 29. J Immunol. 2014. PMID: 25355917
Phenotype of mutations in the promoter region of the β-globin gene.
Ropero P, Erquiaga S, Arrizabalaga B, Pérez G, de la Iglesia S, Torrejón MJ, Gil C, Elena C, Tenorio M, Nieto JM, de la Fuente-Gonzalo F, Villegas A, González Fernández FA, Martínez R. Ropero P, et al. J Clin Pathol. 2017 Oct;70(10):874-878. doi: 10.1136/jclinpath-2017-204378. Epub 2017 Apr 6. J Clin Pathol. 2017. PMID: 28385923
41 results